Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$3.84
-5.7%
$3.70
$2.24
$28.93
$177.89M2.84815,635 shs1.44 million shs
Organogenesis stock logo
ORGO
Organogenesis
$3.67
+1.7%
$3.61
$2.28
$6.71
$465.55M1.631.15 million shs2.22 million shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$10.83
+0.1%
$10.21
$6.65
$12.61
$748.59M0.026,070 shs5,739 shs
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$5.80
+0.9%
$6.28
$3.62
$8.66
$493.55M1.8142,653 shs26,864 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
0.00%-7.02%+3.50%+5.79%-81.72%
Organogenesis stock logo
ORGO
Organogenesis
0.00%+13.62%+28.77%-18.44%+42.25%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.00%+2.13%+2.13%+29.25%+33.82%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
0.00%+2.55%-9.38%-20.11%-21.30%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.3134 of 5 stars
3.32.00.00.02.61.70.6
Organogenesis stock logo
ORGO
Organogenesis
4.4547 of 5 stars
3.03.00.04.32.74.20.6
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.959 of 5 stars
3.55.00.00.02.90.00.6
Valneva SE Sponsored ADR stock logo
VALN
Valneva
1.9792 of 5 stars
3.53.00.00.02.00.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.60
Moderate Buy$29.56669.68% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.00
Hold$6.0063.49% Upside
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
3.00
Buy$30.00177.11% Upside
Valneva SE Sponsored ADR stock logo
VALN
Valneva
3.00
Buy$15.50167.24% Upside

Current Analyst Ratings Breakdown

Latest FDMT, PHAR, VALN, and ORGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (E+)
6/11/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
5/24/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/10/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/9/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $25.00
5/9/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$51.00 ➝ $44.00
5/9/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$45.00 ➝ $38.00
5/8/2025
Valneva SE Sponsored ADR stock logo
VALN
Valneva
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
4/24/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (E+)
4/15/2025
Valneva SE Sponsored ADR stock logo
VALN
Valneva
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
4/9/2025
Valneva SE Sponsored ADR stock logo
VALN
Valneva
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$40K4,447.68N/AN/A$11.05 per share0.35
Organogenesis stock logo
ORGO
Organogenesis
$482.04M0.97$0.21 per share17.59$2.09 per share1.76
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$297.20M2.48$0.07 per share148.44$3.25 per share3.33
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$183.52M2.69$0.10 per share59.36$2.41 per share2.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$160.87M-$3.18N/AN/AN/A-767,126.06%-33.26%-30.68%8/6/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/6/2025 (Estimated)
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$11.84M-$0.20N/A360.87N/A-4.14%-6.01%-3.23%7/30/2025 (Estimated)
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-$13.25M-$1.19N/AN/AN/A-43.08%-43.05%-16.23%8/12/2025 (Estimated)

Latest FDMT, PHAR, VALN, and ORGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$0.84-$0.86-$0.02-$0.86$0.53 millionN/A
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
5/8/2025Q1 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million
5/7/2025Q1 2025
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-$0.40-$0.13+$0.27-$0.13$41.80 million$51.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/A
12.36
12.36
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.39
2.76
2.00
Valneva SE Sponsored ADR stock logo
VALN
Valneva
0.92
2.70
2.12

Institutional Ownership

CompanyInstitutional Ownership
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
99.27%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.03%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
11.39%

Insider Ownership

CompanyInsider Ownership
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
9.60%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.07%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
14.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
12046.33 million41.88 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
28068.03 million66.62 millionNot Optionable
Valneva SE Sponsored ADR stock logo
VALN
Valneva
70085.09 million72.41 millionNot Optionable

Recent News About These Companies

US Advises Older Travelers to Avoid Chikungunya Vaccine

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
4D Molecular Therapeutics stock logo

4D Molecular Therapeutics NASDAQ:FDMT

$3.84 -0.23 (-5.65%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$3.84 +0.01 (+0.13%)
As of 06/27/2025 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$3.67 +0.06 (+1.66%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$3.60 -0.07 (-2.04%)
As of 06/27/2025 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$10.83 +0.01 (+0.06%)
Closing price 06/27/2025 03:57 PM Eastern
Extended Trading
$10.82 0.00 (-0.01%)
As of 06/27/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Valneva stock logo

Valneva NASDAQ:VALN

$5.78 +0.03 (+0.54%)
As of 06/27/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.